Medicus Pharma Reports Q3 2026 Loss of $15.2M; Announces SkinJect SPAC LOI at $135M Valuation
Medicus Pharma reported a Q3 2026 net loss of $15.2 million versus a loss of $16.0 million in Q3 2025, with net loss per share of $11.64 versus $56.18 year-over-year as share counts were retroactively adjusted for the 50-to-1 share consolidation. The Company ended the quarter with $5.0 million in cash and cash equivalents, down from $8.7 million at year-end 2025, following termination of the standby equity purchase agreement with Yorkville in September. The Company announced a non-binding LOI for a proposed Skin...
Key takeaways
Q3 2026 net loss narrowed to $15.2 million from $16.0 million in Q3 2025; net loss per share improved to $11.64 from $56.18 following 50-to-1 share consolidation
Cash and cash equivalents declined to $5.0 million as of September 30, 2026 from $8.7 million at December 31, 2025; total cash including restricted cash was $13.1 million
Operating expenses decreased to $14.5 million from $15.4 million year-over-year; G&A expenses fell to $2.5 million from $5.0 million
R&D expenses increased to $2.0 million from $1.7 million as the Company advanced clinical programs
Medicus entered a co-development and license agreement with Pfizer for CD228V ADC on September 2, 2026, receiving $2.0 million in development funding and designating CD228V as principal development priority
SkinJect announced a non-binding LOI with an undisclosed SPAC for a proposed business combination at approximately $135 million pre-money enterprise valuation with concurrent equity financing
The proposed SkinJect financing would support the SKNJCT-005 registrational Phase 2b study in Gorlin syndrome and potential NDA preparation
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open Investor relationsFollow MDCX in real time
Get material earnings, filing, IR, and earnings-call alerts by email.